Brainsway ( (BWAY) ) has released its Q4 earnings. Here is a breakdown of the information Brainsway presented to its investors.
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments for mental health disorders, is advancing mental health care with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology. The company operates primarily in the medical technology sector, focusing on innovative treatments for conditions such as major depressive disorder and obsessive-compulsive disorder.
In its latest earnings report, BrainsWay announced record quarterly sales of $11.4 million for the fourth quarter of 2024, marking a 27% increase from the same period in 2023. For the full year 2024, the company reported a revenue increase of nearly 30% year-over-year, totaling $41 million. The company also exceeded its operating income and Adjusted EBITDA margin guidance for the year.
Key financial highlights include a net income of $1.5 million for Q4 2024, significantly up from $0.1 million in Q4 2023, and a full-year net income of $2.9 million compared to a net loss in the previous year. BrainsWay also completed a $20 million strategic equity financing transaction with Valor Equity Partners, enhancing its financial position and market reach. The company made strides in clinical trials and expanded its market presence, including entering the Canadian market and increasing its footprint in East Asia.
Looking ahead, BrainsWay projects continued strong growth for 2025, with expected revenue between $49 million and $51 million. The company anticipates further profitability and positive cash flow, driven by its next-generation Deep TMS 360 system and expanded treatment capabilities. BrainsWay remains committed to pioneering advancements in neuromodulation research and expanding access to its Deep TMS technology globally.